



## Infinity Announces Presentations at January Conferences

CAMBRIDGE, Mass., Jan. 7, 2010 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that presentations will be made at several upcoming conferences.

- \* Adelene Q. Perkins, President and Chief Executive Officer, will present a company overview at the J.P. Morgan 28th Annual Healthcare Conference in San Francisco, Calif. on January 14, 2010 at 7:30 a.m. PST.
- \* George D. Demetri, M.D., director of the Ludwig Center at Dana-Farber/Harvard, director of Dana-Farber's Center for Sarcoma and Bone Oncology, and principal investigator of the RING study, a Phase III trial of IPI-504 (retaspimycin hydrochloride) in patients with advanced gastrointestinal stromal tumors, will present final results from the study at the ASCO 2010 Gastrointestinal Cancers Symposium in Orlando, Fla. on January 22, 2010 at 11:30 a.m. EST.
- \* David A. Tuveson, M.D., Ph.D., of Cancer Research UK's Cambridge Research Institute, will present an overview of drug delivery in pancreatic cancer, including preclinical results with Infinity's Hedgehog pathway inhibitor, IPI-926, at the ASCO 2010 Gastrointestinal Cancers Symposium in Orlando, Fla. on January 23, 2010 at 8:00 a.m. EST.

A live webcast of Infinity's presentation at the J.P. Morgan Healthcare Conference will be accessible for thirty days on the company's website at <http://www.infi.com>. In addition, the poster presentation containing the final results from the RING study will be accessible in the Publications Archive section of the company's website after the poster is presented.

### About Infinity Pharmaceuticals, Inc.

Infinity is an innovative cancer drug discovery and development company seeking to discover, develop, and deliver to patients best-in-class medicines for the treatment of cancer and related conditions. Infinity combines proven scientific expertise with a passion for developing novel small molecule drugs that target emerging disease pathways. Infinity's programs in the inhibition of the Hsp90 chaperone system, the Hedgehog pathway and fatty acid amide hydrolase are evidence of its innovative approach to drug discovery and development. For more information on Infinity, please refer to the company's website at <http://www.infi.com>.

CONTACT: Infinity Pharmaceuticals, Inc.  
Monique Allaire  
617-453-1105  
Monique.Allaire@infi.com  
<http://www.infi.com>

(C) Copyright 2010 GlobeNewswire, Inc. All rights reserved.